异动解读｜Iovance Biotherapeutics盘中上涨10.03%，Q2业绩大超预期延续上行动能

行情直击01:13

8月20日，Iovance Biotherapeutics盘中上涨10.03%，报7.735美元/股，成交额1.04亿美元。

消息面上，公司此前发布的第二季度财报大幅超出市场预期，营收约9930万美元，创历史新高，远超分析师预期的8783万美元；每股亏损0.11美元，优于市场预估的亏损0.13-0.14美元，盈利端与收入端均实现双线超预期。强劲的商业化表现推动股价在财报发布后持续走强，当前仍处于业绩驱动的上行通道中。

Iovance Biotherapeutics是一家专注于自体肿瘤浸润淋巴细胞（TIL）疗法开发与商业化的生物技术公司，主要用于治疗转移性黑色素瘤等实体瘤。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1107208733?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-20 01:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107208733","market":"us","top_or_hot":-1,"title":"异动解读｜Iovance Biotherapeutics盘中上涨10.03%，Q2业绩大超预期延续上行动能","media":"行情直击","content":"<p><p>8月20日，Iovance Biotherapeutics盘中上涨10.03%，报7.735美元/股，成交额1.04亿美元。</p><p>消息面上，公司此前发布的第二季度财报大幅超出市场预期，营收约9930万美元，创历史新高，远超分析师预期的8783万美元；每股亏损0.11美元，优于市场预估的亏损0.13-0.14美元，盈利端与收入端均实现双线超预期。强劲的商业化表现推动股价在财报发布后持续走强，当前仍处于业绩驱动的上行通道中。</p><p>Iovance Biotherapeutics是一家专注于自体肿瘤浸润淋巴细胞（TIL）疗法开发与商业化的生物技术公司，主要用于治疗转移性黑色素瘤等实体瘤。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜Iovance Biotherapeutics盘中上涨10.03%，Q2业绩大超预期延续上行动能</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜Iovance Biotherapeutics盘中上涨10.03%，Q2业绩大超预期延续上行动能\n</h2>\n\n<h4 class=\"meta\">\n\n2026-08-20 01:13 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月20日，Iovance Biotherapeutics盘中上涨10.03%，报7.735美元/股，成交额1.04亿美元。消息面上，公司此前发布的第二季度财报大幅超出市场预期，营收约9930万美元，创历史新高，远超分析师预期的8783万美元；每股亏损0.11美元，优于市场预估的亏损0.13-0.14美元，盈利端与收入端均实现双线超预期。强劲的商业化表现推动股价在财报发布后持续走强，当前仍处于业绩...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"","article_id":"1107208733","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107208733","pubTimestamp":1787159599,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"8月20日，Iovance Biotherapeutics盘中上涨10.03%，报7.735美元/股，成交额1.04亿美元。强劲的商业化表现推动股价在财报发布后持续走强，当前仍处于业绩驱动的上行通道中。Iovance Biotherapeutics是一家专注于自体肿瘤浸润淋巴细胞疗法开发与商业化的生物技术公司，主要用于治疗转移性黑色素瘤等实体瘤。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"Interpretation of unusual changes | Iovance Biotherapeutics rose 10.03% intraday, Q2 performance greatly exceeded expectations and continued its upward movement","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":1},"content_text":"8月20日，Iovance Biotherapeutics盘中上涨10.03%，报7.735美元/股，成交额1.04亿美元。消息面上，公司此前发布的第二季度财报大幅超出市场预期，营收约9930万美元，创历史新高，远超分析师预期的8783万美元；每股亏损0.11美元，优于市场预估的亏损0.13-0.14美元，盈利端与收入端均实现双线超预期。强劲的商业化表现推动股价在财报发布后持续走强，当前仍处于业绩驱动的上行通道中。Iovance Biotherapeutics是一家专注于自体肿瘤浸润淋巴细胞（TIL）疗法开发与商业化的生物技术公司，主要用于治疗转移性黑色素瘤等实体瘤。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107208733","isCrawlerRequest":true}